$59.090
-0.130 (-0.22%)收盤時
DAR 資訊
DAR 事件
Darling Ingredients Releases Q3 2026 Earnings Report
Darling Ingredients issued the following statement regarding third quarter earnings. "Third quarter 2026 earnings for Darling Ingredients' 50/50 joint venture known as Diamond Green Diesel were released today by Darling Ingredients' joint venture partner within its renewable diesel segment as part of its third quarter consolidated results. The JV partner today reported that its renewable diesel segment earned approximately $350 million in operating income for the three months ended Sept. 30, 2026. For the nine months ended Sept. 30, 2026, the JV partner reported that its renewable diesel segment earned approximately $1.3 billion in operating income. In the three months ended Sept. 30, 2026, DGD sold/shipped 314.9 million gallons of renewable fuels. For the nine months ended Sept. 30, 2026, DGD sold/shipped 936.1 million gallons of renewable fuels. As determined on a stand-alone basis by Darling Ingredients, DGD Adjusted EBITDA per gallon for the three months ended Sept. 30, 2026, was $1.30. As determined on a stand-alone basis by Darling Ingredients, DGD Adjusted EBITDA per gallon for the nine months ended Sept. 30, 2026, was $1.59." "Diamond Green Diesel delivered a solid quarter. While results were impacted by the timing of renewable diesel sales and certain commercial activities, we expect those timing differences to benefit fourth-quarter results," said Randall Stuewe, Chairman and Chief Executive Officer. "The fundamentals of our core business remain strong, and we remain focused on delivering on our objectives for the year. We have strong momentum into fourth quarter and expect that to continue into 2027. Supported by strong business fundamentals and a favorable run rate entering the fourth quarter, the company is providing fiscal year 2026 Combined Adjusted EBITDA guidance for Darling Ingredients of $2.2-$2.3 billion and expects to carry that momentum into 2027."
Darling Ingredients Sells CTH Sausage Casing Business to SARIA
Darling Ingredients closed on the sale of its CTH branded sausage casing business to SARIA for an undisclosed amount. "The sale of CTH illustrates our continued commitment to optimizing our portfolio and positioning Darling Ingredients for continued growth," said Randall C. Stuewe, Chairman and Chief Executive Officer. "We are committed to channeling our efforts toward segments with strong integration and long-term value creation potential, while using the proceeds to further our goal of reducing debt."
Darling Ingredients Announces Agreement to Sell $150 Million Production Tax Credits
Darling Ingredients "announced an agreement to sell approximately $150 million of production tax credits to a corporate buyer. These credits were generated under the Inflation Reduction Act by the company's Diamond Green Diesel joint venture. The proceeds of the sale are scheduled to be received by the end of the third quarter, upon satisfaction of certain funding conditions."
Darling Ingredients Increases Share Repurchase Program to $1B
Darling Ingredients announced that the Board of Directors has refreshed and increased its share repurchase program to $1B. "As our balance sheet continues to strengthen and cash generation accelerates, we have the flexibility to invest in our business, pursue attractive organic growth opportunities and return capital to our shareholders," said Randall C. Stuewe, Chairman and Chief Executive Officer. "This share repurchase program reflects our confidence in Darling's future and demonstrates our commitment to delivering long-term shareholder value."
Darling Ingredients Secures Patent for Nextida GC
Darling Ingredients and its health brand Rousselot announced that the U.S. Patent and Trademark Office has granted Patent No. US12636339 for Nextida GC, a first-of-its-kind collagen peptide ingredient developed to help support healthy after-meal blood sugar levels, naturally. The patent protects both the production process and the use of Nextida GC as a dietary supplement ingredient, offering a non-pharmaceutical option for managing blood glucose through science-backed nutrition.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。




